Bellevue Life Sciences Acquisition Corp. Rights
BLACR
BLACR was delisted on the 14th of February, 2025.
0 hedge funds and large institutions have $0 invested in Bellevue Life Sciences Acquisition Corp. Rights in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 28 closing their positions.
100% less funds holding
Funds holding: 28 → 0 (-28)
100% less capital invested
Capital invested by funds: $681K → $0 (-$681K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 28
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$100K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$65.2K |
| 3 |
HCI
Harraden Circle Investments
New York
|
-$58.3K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$48.7K |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$46.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIA
26
Schechter Investment Advisors
Birmingham,
Michigan
| – | -$1.77K | -15,500 | Closed |
|
|
WC
27
Wealthspring Capital
West Harrison,
New York
| – | -$1.36K | -11,900 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | -$11 | -100 | Closed |
|
BLACR Hedge Fund Activity: Q1 2025 in Review
0 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q1 2025, worth a combined $0 — down 100% from $681K a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of BLACR and 0 opened new positions — a net loss of 28 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Highbridge Capital Management, exiting entirely with an estimated $100K sold.
- 0 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q1 2025, down from 28 in Q4 2024.
- Funds reported $0 of Bellevue Life Sciences Acquisition Corp. Rights stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q1 2025 and 28 closed out, a net change of -28 holders.
- The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q1 2025 was Highbridge Capital Management, an estimated $100K sold.
Based on aggregated 13F filings for Q1 2025.